Coherus Oncology (CHRS) Receivables - Other: 2013-2025
Historic Receivables - Other for Coherus Oncology (CHRS) over the last 3 years, with Sep 2025 value amounting to $241.3 million.
- Coherus Oncology's Receivables - Other rose 672.23% to $241.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $241.3 million, marking a year-over-year increase of 672.23%. This contributed to the annual value of $11.0 million for FY2024, which is N/A change from last year.
- According to the latest figures from Q3 2025, Coherus Oncology's Receivables - Other is $241.3 million, which was up 110.64% from $114.5 million recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Receivables - Other ranged from a high of $241.3 million in Q3 2025 and a low of $1.9 million during Q1 2025.
- In the last 2 years, Coherus Oncology's Receivables - Other had a median value of $32.2 million in 2024 and averaged $81.5 million.
- Data for Coherus Oncology's Receivables - Other shows a peak YoY increase of 672.23% (in 2025) and a maximum YoY decrease of 93.95% (in 2025) over the last 5 years.
- Coherus Oncology's Receivables - Other (Quarterly) stood at $11.0 million in 2024, then soared by 672.23% to $241.3 million in 2025.
- Its last three reported values are $241.3 million in Q3 2025, $114.5 million for Q2 2025, and $1.9 million during Q1 2025.